biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > I sure like this Jon

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Sep 30, 2023 11:51am

111 Views

Post# 35663252

RE:RE:RE:RE:I sure like this Jon

"the case can be made that all studies have shown that it works." However, studies have not been done on humans as yet.

And is there a danger of diseases in the bloodstream crossing the BBB into the brain with the aid of Bioasis and other like drugs?

G1945V

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023